Panacea Biotec announced that its material wholly owned subsidiary, . Panacea Biotec Pharma (PBPL) has fully redeemed the entire outstanding NCDs aggregating Rs 754.44 crore together with redemption premium of Rs 343.63 crore, out of the funds received by it in consideration of the sale of domestic pharmaceutical formulations brands in Nepal and India held by PBPL.
As a result, PBPL has now become a debt free company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
